CURRENT SERIES:
Prostate Cancer
November 26, 2013
December 17, 2013
December 17, 2013
January 10, 2014
January 10, 2014
February 19, 2014
NOW PLAYING
Episode 7 - Treatment Coverage in Castration-Resistant Prostate Cancer
7 of 13
February 19, 2014
March 21, 2014
April 22, 2014
April 22, 2014
May 20, 2014
May 20, 2014

Episode 7 - Treatment Coverage in Castration-Resistant Prostate Cancer

During this segment, the panelists explore issues faced by managed care during treatment coverage decisions in castration-resistant prostate cancer (CRPC).
During this segment, the panelists explore issues faced by managed care during treatment coverage decisions in castration-resistant prostate cancer (CRPC).

Michael Kolodziej, MD, discusses the high costs of newly developed agents, their role in drug-sequencing plans, and the Affordable Care Act’s impact on treatment coverage in CRPC.

Jeffrey D. Dunn, PharmD, MBA, explains the need for improvements in the research that can help provide better data about a drug’s effectiveness, and can help professionals determine a product’s cost and availability for health coverage.

David Quinn, MD, agrees with Dr Dunn and suggests that a patient’s improvements in health and overall outcomes must be additive to the cost of therapy. Dr Quinn further explains that by studying the value of agents used to treat CRPC, a paradigm shift may provide results about the benefits of options given to treat patients over a sequence of time.




 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up